Strategic Stocks To Watch ALLEZOE MEDICAL HOLDINGS INCORPORATED (OTC: ALZM)
Up 251.82% on Tuesday
Allezoe Medical Holdings, Inc. is a holding company focused on acquiring the most high quality and in-demand medical products, solutions and services. Whether through diagnosis, treatment, or medical research itself, Allezoe is interested in companies that are making a striking difference in the healthcare system through technology and treatments for health issues that affect large populations.
ALZM News:
December 20 – Allezoe Medical Holdings (ALZM) Completes Exclusive Licensing Deal for HPV Diagnostic Technology
12-21-11 Strategic Stocks To Watch ALLEZOE MEDICAL HOLDINGS INCORPORATED (OTC: ALZM)
Allezoe Medical Holdings, Inc. (OTCBB: ALZM) announces that it has acquired the exclusive license to develop and market patent pending, advanced “see and treat” diagnostic technology for Human papillomavirus (HPV), the world’s leading sexually transmitted infection (STI). An exclusive license has been signed by SureScreen Medical, Inc., a wholly-owned subsidiary of Allezoe, and AVM Corp., which recently acquired the technology and the pending patent application from its developer, Aequorea Vision Medical, Inc. Under the terms of the license, SureScreen will develop and market products worldwide using the technology in return for a fixed royalty to AVM, commencing on sales of products using the technology.
As a result of the license, Allezoe now holds the exclusive worldwide rights to this groundbreaking “see and treat” technology which will allow healthcare providers to identify cell damage from HPV instantaneously, bypassing the long lab wait times, fees and additional patient discomfort found in existing HPV diagnostic methods on the market, including the Pap smear.
With this license and the global marketing and distribution strategy it is developing, Allezoe will be positioned to enter its market. In the United States alone, there is a $6 billion annual diagnosis and treatment market for HPV, and the market is increasing under growing national attention to the virus. Recently, the Centers for Disease Control and Prevention has recommended the HPV vaccine be used for men as well. Allezoe’s technology is a crucial counterpart to the vaccine, identifying any preexisting damage before vaccine administration; importantly, it also offers an important alternative for those who avoid the vaccine due to controversial side effects.
Infecting 233 million women worldwide, the virus is the leading cause of cervical cancer in women, which often results in death. HPV is known to cause a growing number of cancers and lesions in both genders, including cervical, neck, and throat cancer. More recently, HPV is being researched as a possible cause of heart disease. Allezoe’s technology is a one-stop HPV solution for patients and their providers. Allezoe’s HPV technology will be welcome in the United States, where healthcare costs are a growing concern. It has important implications for healthcare abroad and in poorer nations where patients do not have the luxury of making repeated visits to a clinic or waiting several days for a Pap smear report from a distant laboratory.
Allezoe CEO Michael Gelmon says, “This is not a virus we have the luxury of ignoring, when hundreds of millions of people around the world are affected and are further spreading the virus. Our new licensed technology offers the combination of accuracy plus efficiency. This is a large market that we are looking forward to penetrating, and we have a strategy in place so we can hit the ground running.”
If you find our information valuable, Subscribe to Strategic Stocks and Penny Stocks RSS Feed by e-mail, to Receive our Updates INSTANTLY, and share this post/page with your friends and followers with use of the Social Buttons.
Like all investment strategies, trading in stocks involves risk and volatility. Past performance is not an indication of future results. Actual results will be based on a consumer’s individual purchase and sale decisions.
Please read our Disclaimer regards to ALZM or any company reviewed or blogged about at Strategic Penny Stocks.
